Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML

Inclusion Criteria: * Subjects eligible for enrollment in this study must meet all of the following criteria: 1. Diagnosis of acute myeloid leukemia (AML) according to the WHO 2022 or ICC criteria, excluding acute promyelocytic leukemia (APL). 2. No prior therapy for AML, except hydroxyurea for the management of hyperleukocytosis. 3. Meeting at least one of the following criteria: 1. Age ≥ 75 years; 2. Age 18-74 years with at least one of the following conditions precluding suitability for intensive chemotherapy: i. ECOG performance status 2-3; ii. Cardiac dysfunction with left ventricular ejection fraction (LVEF) ≤ 50%; iii. Pulmonary dysfunction with diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or forced expiratory volume in 1 second (FEV1) ≤ 65%; iv. Creatinine clearance 30-45 mL/min; v. Other major organ dysfunction or comorbidities that, in the investigator's judgment, render the patient unsuitable for intensive chemotherapy. 4. ECOG performance status 0-3. 5. Life expectancy ≥ 3 months. 6. Patients of childbearing potential agree to use effective contraception during the treatment period and for at least 6 months after the last dose of study treatment. 7. Voluntary written informed consent provided. Exclusion Criteria: * Subjects who meet any of the following criteria will not be eligible for enrollment in this study: 1. Acute promyelocytic leukemia (APL).. 2. Active central nervous system (CNS) leukemia. 3. Prior targeted therapy or chemotherapy for AML, excluding hydroxyurea. 4. Uncontrolled active infection. 5. Uncontrolled cardiovascular disease: New York Heart Association (NYHA) class III-IV heart failure, myocardial infarction or unstable angina within 6 months before enrollment, or uncontrolled hypertension. 6. Left ventricular ejection fraction (LVEF) \< 40%. 7. Concurrent active malignancy, except for cured non-melanoma skin cancer, carcinoma in situ of the cervix, or localized prostate cancer. 8. Known hypersensitivity to the study drugs or their excipients. 9. Pregnant or breastfeeding women. 10. Any other condition that, in the investigator's judgment, would make the patient unsuitable for study participation.